Latest Pyrazines Stories
Response Rate Increases to 41% and Median Overall Survival Reported at 25 Months for All Evaluable Patients QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S.
NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S.
Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens.
SOUTH SAN FRANCISCO, Oct. 17 /PRNewswire/ -- Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.
SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX).
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.